You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Any dealt with MRSA?
- Thread starter vinsmom
- Start date
Emily65Roses
New member
I got MRSA when I was almost 17. Though I guess that was still pediatrics, huh?
Emily65Roses
New member
I got MRSA when I was almost 17. Though I guess that was still pediatrics, huh?
Emily65Roses
New member
I got MRSA when I was almost 17. Though I guess that was still pediatrics, huh?
Emily65Roses
New member
I got MRSA when I was almost 17. Though I guess that was still pediatrics, huh?
Emily65Roses
New member
I got MRSA when I was almost 17. Though I guess that was still pediatrics, huh?
Hi Lauren-
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Hi Lauren-
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Hi Lauren-
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Hi Lauren-
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Hi Lauren-
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
Yes, it is used to successfully treat adults as well. Interestingly, the Europeans and Austrailians are using much more than the US doctors....I have no idea why...
One thing I think we should all keep in mind...this was an emerging pathogen in CF with a few articles being written on it in 1988. Now, it is considered a very important pathogen that is being treated, in most cases, immediately upon culturing it because colonization is leading to lung function deterioration.
****ALSO*****
Much of the research I have dug up states that this pathogen is mainly acquired in hospital or clinic setting.
TIPS FOR STAYING GERM FREE AT CLINIC
**WASH YOUR HANDS
**DON'T LEAN ON COUNTERS AT CLINIC....ESPECIALLY WHEN CHECKING IN. THEY ARE SO BUSY CLEANING ROOMS THEY FORGET ABOUT THE ONE PLACE EVERYONE GOES...CHECK IN DESK.
**BRING YOUR OWN PEN (they pass around pens and every patient uses the same ones)
**DON'T WRITE ON THE CLINIC CLIPBOARD.....(for Pete's sake, they do not wipe these down between patients!!!!!! Bring a magazine to write on if your leg is skinny!!)
**LADIES NEVER SET OUR PURSE DOWN ON COMMON SURFACES. PUT IT ON YOUR LAP AND THEN THE EXAMINATION TABLE THAT IS COVERED.
**NEVER TOUCH YOUR FACE WHEN AT CLINIC...NO SCRATCHY SCRATCHY!!....
**SHOWER AFTER CLINIC
<b>Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection.
</b>
Garske LA, Kidd TJ, Gan R, Bunting JP, Franks CA, Coulter C, Masel PJ, Bell SC.
Adult Cystic Fibrosis Unit, and Queensland Health Pathology Services, The Prince Charles Hospital, Brisbane, QLD, Australia.
Nosocomial transmission of methicillin-resistant Staphylococcus aureus (MRSA) to patients with cystic fibrosis (CF) frequently results in chronic respiratory tract carriage. This is an increasing problem, adds to the burden of glycopeptide antibiotic use in hospitals, and represents a relative contraindication to lung transplantation. <b>The aim of this study was to determine whether it is possible to eradicate MRSA with prolonged oral combination antibiotics, and whether this treatment is associated with improved clinical status.</b> Adult CF patients (six male, one female) with chronic MRSA infection were treated for six months with rifampicin and sodium fusidate. Outcome data were examined for six months before treatment, on treatment and after treatment. The patients had a mean age of 29.3 (standard deviation=6.3) years and FEV(1) of 36.1% (standard deviation=12.7) predicted. The mean duration of MRSA isolation was 31 months. <b>MRSA isolates identified in these patients was of the same lineage as the known endemic strain at the hospital when assessed by pulsed-field gel electrophoresis</b>. Five of the seven had no evidence of MRSA during and for at least six months after rifampicin and sodium fusidate. The proportion of sputum samples positive for MRSA was lower during the six months of treatment (0.13) and after treatment (0.19) compared with before treatment (0.85) (P<0.0001). There was a reduction in the number of days of intravenous antibiotics per six months with 20.3+/-17.6 on treatment compared with 50.7 before treatment and 33.0 after treatment (P=0.02). There was no change in lung function. Gastrointestinal side effects occurred in three, but led to therapy cessation in only one patient. Despite the use of antibiotics with anti-staphylococcal activity for treatment of respiratory exacerbation, MRSA infection persists<b>. MRSA can be eradicated from the sputum of patients with CF and chronic MRSA carriage by using rifampicin and sodium fusidate for six months.</b> This finding was associated with a significant reduction in the duration of intravenous antibiotic treatment during therapy.
J Cyst Fibros. 2005 Sep;4(3):205-7. Links
MRSA eradication in a health care worker with cystic fibrosis; re-emergence or re-infection?
Downey DG, Kidd TJ, Coulter C, Bell SC.
Adult Cystic Fibrosis Unit, Brisbane, QLD, Australia.
Methicillin-resistant Staphylocosis aureus (MRSA) is an emerging infection in patients with cystic fibrosis (CF). MRSA may be a management dilemma for healthcare workers (HCWs) with CF. <b>Eradication of MRSA with long-term rifampicin and fusidic acid can be achieved in patients with CF.</b> We describe a case of recurrent MRSA infection in a HCW with CF. Molecular typing of the MRSA isolates supported re-infection rather than re-emergence of an earlier MRSA infection. Infection control advice for HCWs with CF who acquire MRSA remains controversial.
J Cyst Fibros. 2005 Mar;4(1):49-52. Links
Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis.
Nadesalingam K, Conway SP, Denton M.
Division of Microbiology, University of Leeds, Leeds, UK.
Methicillin-resistant Staphylococcus aureus (MRSA) is an increasing problem for patients with cystic fibrosis (CF). It has been associated with clinical deterioration in some patients with CF, creates additional infection control problems, and may affect acceptance onto transplant waiting lists. Recent attempts to eradicate the organism have met with only moderate success. An understanding of those factors which increase the risk of acquisition of MRSA by CF patients will aid the development of effective preventative strategies. We conducted a retrospective case-control study comparing a variety of risk factors for 15 MRSA-positive patients and 30 age-sex-matched MRSA-negative controls who attended the Regional Paediatric or Regional Adult Cystic Fibrosis Units in Leeds. During the year prior to initial isolation, MRSA-positive CF patients spent more days in hospital (mean 19.8 days versus 5.5 days, p=0.0003), received more treatment days of oral ciprofloxacin (43.5 days versus 13.9 days, p=0.03) more treatment days of oral/intravenous cephalosporins (42.7 days versus 15.4 days, p=0.04) and were more likely to be chronically infected with Aspergillus fumigatus (40% versus 10%, p=0.04) than the age-sex-matched MRSA-negative controls. There were no significant differences in observed clinical parameters (clinical and X-ray scores) with between the two groups. Minimising the number and length of hospital admissions and judicious use of antibiotics, particularly ciprofloxacin, should be the key components of any strategies designed to reduce the risk of MRSA acquisition by patients with CF.
coltsfan715
New member
I personally would say push for treatment. I started culturing MRSA at 15 and never was treated for it until I became an adult. I personally could have been saved ALOT of grief had it been treated initially and possibly eradicated at that time.
Best of Luck,
Lindsey
Best of Luck,
Lindsey
coltsfan715
New member
I personally would say push for treatment. I started culturing MRSA at 15 and never was treated for it until I became an adult. I personally could have been saved ALOT of grief had it been treated initially and possibly eradicated at that time.
Best of Luck,
Lindsey
Best of Luck,
Lindsey
coltsfan715
New member
I personally would say push for treatment. I started culturing MRSA at 15 and never was treated for it until I became an adult. I personally could have been saved ALOT of grief had it been treated initially and possibly eradicated at that time.
Best of Luck,
Lindsey
Best of Luck,
Lindsey
coltsfan715
New member
I personally would say push for treatment. I started culturing MRSA at 15 and never was treated for it until I became an adult. I personally could have been saved ALOT of grief had it been treated initially and possibly eradicated at that time.
Best of Luck,
Lindsey
Best of Luck,
Lindsey
coltsfan715
New member
I personally would say push for treatment. I started culturing MRSA at 15 and never was treated for it until I became an adult. I personally could have been saved ALOT of grief had it been treated initially and possibly eradicated at that time.
Best of Luck,
Lindsey
Best of Luck,
Lindsey